Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2-subgroup using diffuse optical tomography

被引：0
|
作者：
Altoe, Mirella L. [1 ]
Marone, Alessandro [1 ]
Kim, Hyun K. [1 ,2 ]
Guo, Hua [3 ]
Hibshoosh, Haninna [3 ]
Tejada, Mariella [4 ]
Crew, Katherine D. [4 ,5 ]
Accordino, Melissa K. [4 ]
Trivedi, Meghna S. [4 ]
Kalinsky, Kevin [4 ]
Hershman, Dawn L. [4 ,5 ]
Hielscher, Andreas H. [1 ]
机构：
[1] NYU, Tandon Sch Engn, Dept Biomed Engn, Brooklyn, NY 11201 USA
[2] Columbia Univ, Dept Radiol, Irving Med Ctr, New York, NY 10032 USA
[3] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10032 USA
[4] Columbia Univ, Dept Med, Irving Med Ctr, Div Hematol Oncol, New York, NY 10032 USA
[5] Columbia Univ, Dept Epidemiol, Irving Med Ctr, New York, NY 10032 USA
来源：
MULTISCALE IMAGING AND SPECTROSCOPY III | 2022年 / 11944卷
关键词：
Difuse optical tomography; deoxy-hemoglobin; breast cancer; neoadjuvant chemotherapy; pCR; molecular subtype; HR+/HER2-;
D O I：
10.1117/12.2609729
中图分类号：
R318 [生物医学工程];
学科分类号：
0831 ;
摘要：
This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS)during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 +/- 0.22) as compared to patients with a non-pCR (1.14 +/- 0.24, P <.005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2-Breast Cancer Patients
    Oprea, Adela Luciana
    Gulluoglu, Bahadir
    Aytin, Yusuf Emre
    Eren, Ozgur Can
    Aral, Canan
    Szekely, Tiberiu-Bogdan
    Tastekin, Ebru
    Kaya, Handan
    Bademler, Sueleyman
    Karanlik, Hasan
    Sezer, Atakan
    Ugurlu, Mustafa Umit
    Turdean, Sabin Gligore
    Georgescu, Rares
    Marginean, Claudiu
    BREAST CARE, 2023, 18 (05) : 344 - 353
  • [2] Predicting Treatment Response of Breast Cancer to Neoadjuvant Chemotherapy Using Ultrasound-Guided Diffuse Optical Tomography
    Zhi, Wenxiang
    Liu, Guangyu
    Chang, Cai
    Miao, Aiyu
    Zhu, Xiaoli
    Xie, Li
    Zhou, Jin
    TRANSLATIONAL ONCOLOGY, 2018, 11 (01): : 56 - 64
  • [3] Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography
    Zhu, Quing
    Ademuyiwa, Foluso O.
    Young, Catherine
    Appleton, Catherine
    Covington, Matthew F.
    Ma, Cynthia
    Sanati, Souzan
    Hagemann, Ian S.
    Mostafa, Atahar
    Uddin, K. M. Shihab
    Grigsby, Isabella
    Frith, Ashley E.
    Hernandez-Aya, Leonel F.
    Poplack, Steven S.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (03) : 615 - 630
  • [4] Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography
    Quing Zhu
    Foluso O. Ademuyiwa
    Catherine Young
    Catherine Appleton
    Matthew F. Covington
    Cynthia Ma
    Souzan Sanati
    Ian S. Hagemann
    Atahar Mostafa
    K. M. Shihab Uddin
    Isabella Grigsby
    Ashley E. Frith
    Leonel F. Hernandez-Aya
    Steven S. Poplack
    Breast Cancer Research and Treatment, 2021, 188 : 615 - 630
  • [5] Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy
    Cerussi, Albert
    Hsiang, David
    Shah, Natasha
    Mehta, Rita
    Durkin, Amanda
    Butler, John
    Tromberg, Bruce J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (10) : 4014 - 4019
  • [6] Predicting Breast Tumor Response to Neoadjuvant Chemotherapy with Diffuse Optical Spectroscopic Tomography prior to Treatment
    Jiang, Shudong
    Pogue, Brian W.
    Kaufman, Peter A.
    Gui, Jiang
    Jermyn, Michael
    Frazee, Tracy E.
    Poplack, Steven P.
    DiFlorio-Alexander, Roberta
    Wells, Wendy A.
    Paulsen, Keith D.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 6006 - 6015
  • [7] Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters
    Quing Zhu
    Susan Tannenbaum
    Scott H. Kurtzman
    Patricia DeFusco
    Andrew Ricci
    Hamed Vavadi
    Feifei Zhou
    Chen Xu
    Alex Merkulov
    Poornima Hegde
    Mark Kane
    Liqun Wang
    Kert Sabbath
    Breast Cancer Research, 20
  • [8] Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters
    Zhu, Quing
    Tannenbaum, Susan
    Kurtzman, Scott H.
    DeFusco, Patricia
    Ricci, Andrew, Jr.
    Vavadi, Hamed
    Zhou, Feifei
    Xu, Chen
    Merkulov, Alex
    Hegde, Poornima
    Kane, Mark
    Wang, Liqun
    Sabbath, Kert
    BREAST CANCER RESEARCH, 2018, 20
  • [9] Using Diffuse Optical Tomography to Monitor Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
    Gunther, Jacqueline E.
    Lim, Emerson
    Kim, Hyun Keol
    Flexman, Molly
    Brown, Mindy
    Refrice, Susan
    Kalinsky, Kevin
    Hershman, Dawn
    Hielscher, Andreas H.
    OPTICAL TOMOGRAPHY AND SPECTROSCOPY OF TISSUE X, 2013, 8578
  • [10] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
12345